Evommune

Advertisement

cGxPJobs Banner

Evommune Reports Phase 2b Setback for EVO756 in Atopic Dermatitis

PALO ALTO, Calif. and NEW YORK — September 8, 2026 Evommune, Inc. announced top-line results from its randomized, double-blind,...

By cGxPwire Editor
September 10, 2026

Read More

Evommune Launches Phase 2b Trial of EVO756 for Migraine Prevention

PALO ALTO, Calif., & NEW YORK, July 30, 2026 Evommune announced that the first patient has been dosed in...

By cGxPwire Editor
July 31, 2026

Read More

Advertisement

cGxPJobs

Directory